Chad F. Phipps, Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary of Zimmer Biomet Holdings, Inc., filed a Form 4 on September 9, 2026, disclosing a sale of common stock that occurred on September 4, 2026.

Key Highlights

  • Shares sold: Chad F. Phipps disposed of 3,000 shares of Zimmer Biomet common stock on September 4, 2026.
  • Sale price: The shares were sold at $98.35 each, according to the filing.
  • Remaining ownership: Following the transaction, Phipps beneficially owned 65,231 shares directly.
  • ESPP and dividend reinvestment: The post-transaction total includes 471 shares acquired under the Employee Stock Purchase Plan and through dividend reinvestment through July 31, 2026.
  • Transaction code: The disposal was recorded under transaction code S, indicating an open-market sale.
  • Filing agent: The form was signed by Matthew R. St. Louis as attorney-in-fact for Chad F. Phipps, pursuant to a previously filed power of attorney.

Phipps Disposition Details and Beneficial Ownership at Zimmer Biomet

According to the Form 4 filed with the SEC on September 9, 2026, Chad F. Phipps, who serves as Senior Vice President, Chief Legal and Corporate Affairs Officer and Secretary of Zimmer Biomet Holdings, Inc. (NYSE:ZBH), reported the sale of 3,000 shares of the company's common stock. The transaction was dated September 4, 2026, and the shares were disposed of at a price of $98.35 per share.

Following the reported sale, Phipps held 65,231 shares of common stock on a direct basis, the filing disclosed. A footnote in the filing states that this total includes 471 shares acquired under the Employee Stock Purchase Plan and pursuant to dividend reinvestment through July 31, 2026. No derivative securities transactions were reported in Table II of the filing.

The Form 4 was signed on September 9, 2026, by Matthew R. St. Louis as attorney-in-fact for Chad F. Phipps, with the filing noting that the power of attorney was previously filed. The form was filed by one reporting person, and the transaction was recorded as a direct ownership disposition with no indirect holdings reported in connection with this filing.

What Was Disclosed

The filing reports a single open-market sale of 3,000 shares of Zimmer Biomet common stock by an officer on September 4, 2026, at $98.35 per share, leaving the officer with 65,231 directly held shares following the transaction.